India’s pharmaceutical exports remained strong in April and May 2025, at USD 4.96 billion, according to the Pharmaceuticals Export Promotion Council of India (Pharmexcil). Exports reached USD 2.47 billion in May alone, representing a 7.38% increase over the same period last year. 

This expansion is driven by rising global demand, more efficient regulatory clearances, digital initiatives, and India’s efforts to expand its international presence.

Formulations and biologicals continued to lead, making up 75.74% of total exports. Bulk medicines and intermediates increased by 4.40%, while vaccines jumped by 13.64% to USD 190.13 million. Surgical items increased by 8.58% to USD 124.62 million, while Ayurvedic and herbal products gained by 7.36% to USD 119.89 million.

NAFTA, Europe, Africa, and Latin America remained significant markets, accounting for 76% of total exports. The ASEAN area increased its contribution to 4.88%. The top five markets were the US, UK, Brazil, South Africa, and France, with US exports rising 1.5% to USD 1.71 billion. Exports to Europe increased by 3.14%, while Africa increased by 1.71%.

Pharmexcil is preparing for iPHEX 2025, which will highlight India’s pharmaceutical strengths and establish worldwide connections.